Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Telomere length regulation through epidermal growth factor receptor signaling in cancer.

Augustine T, Maitra R, Goel S.

Genes Cancer. 2017 May;8(5-6):550-558. doi: 10.18632/genesandcancer.140. Review.

2.

Primary and acquired resistance to biologic therapies in gastrointestinal cancers.

Lubner SJ, Uboha NV, Deming DA.

J Gastrointest Oncol. 2017 Jun;8(3):499-512. doi: 10.21037/jgo.2017.01.16. Review.

3.

Development of a Whole Organism Platform for Phenotype-Based Analysis of IGF1R-PI3K-Akt-Tor Action.

Liu C, Dai W, Bai Y, Chi C, Xin Y, He G, Mai K, Duan C.

Sci Rep. 2017 May 17;7(1):1994. doi: 10.1038/s41598-017-01687-3.

4.

PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.

Xu JM, Wang Y, Wang YL, Wang Y, Liu T, Ni M, Li MS, Lin L, Ge FJ, Gong C, Gu JY, Jia R, Wang HF, Chen YL, Liu RR, Zhao CH, Tan ZL, Jin Y, Zhu YP, Ogino S, Qian ZR.

Clin Cancer Res. 2017 Aug 15;23(16):4602-4616. doi: 10.1158/1078-0432.CCR-16-2738. Epub 2017 Apr 19.

PMID:
28424201
5.

EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.

Yamamoto I, Nosho K, Kanno S, Igarashi H, Kurihara H, Ishigami K, Ishiguro K, Mitsuhashi K, Maruyama R, Koide H, Okuda H, Hasegawa T, Sukawa Y, Okita K, Takemasa I, Yamamoto H, Shinomura Y, Nakase H.

Oncotarget. 2017 Mar 14;8(11):17810-17818. doi: 10.18632/oncotarget.14863.

6.

The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.

De Rosa M, Rega D, Costabile V, Duraturo F, Niglio A, Izzo P, Pace U, Delrio P.

Therap Adv Gastroenterol. 2016 Nov;9(6):861-886. Epub 2016 Aug 7. Review.

7.
8.

The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms.

Sievers CK, Kratz JD, Zurbriggen LD, LoConte NK, Lubner SJ, Uboha N, Mulkerin D, Matkowskyj KA, Deming DA.

Clin Colon Rectal Surg. 2016 Sep;29(3):232-8. doi: 10.1055/s-0036-1584292. Review.

PMID:
27582648
9.

Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen.

Lopez NE, Peterson CY.

Clin Colon Rectal Surg. 2016 Sep;29(3):196-204. doi: 10.1055/s-0036-1584289. Review.

PMID:
27582644
10.

Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.

Mei ZB, Duan CY, Li CB, Cui L, Ogino S.

Ann Oncol. 2016 Oct;27(10):1836-48. doi: 10.1093/annonc/mdw264. Epub 2016 Jul 19. Review.

PMID:
27436848
11.

PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study.

Kuramochi H, Nakamura A, Nakajima G, Kaneko Y, Araida T, Yamamoto M, Hayashi K.

BMC Cancer. 2016 Jun 13;16:366. doi: 10.1186/s12885-016-2400-4.

12.

Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS.

Liu J, Hu J, Cheng L, Ren W, Yang M, Liu B, Xie L, Qian X.

Onco Targets Ther. 2016 Jan 27;9:557-65. doi: 10.2147/OTT.S86966. eCollection 2016. Review.

13.

Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.

Lech G, Słotwiński R, Słodkowski M, Krasnodębski IW.

World J Gastroenterol. 2016 Feb 7;22(5):1745-55. doi: 10.3748/wjg.v22.i5.1745. Review.

14.

Pharmacologic resistance in colorectal cancer: a review.

Hammond WA, Swaika A, Mody K.

Ther Adv Med Oncol. 2016 Jan;8(1):57-84. doi: 10.1177/1758834015614530. Review.

15.

Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.

Lin L, Zhang Z, Zhang W, Wang L, Wang J.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):13314-22. eCollection 2015.

16.

Precision medicine in colorectal cancer: the molecular profile alters treatment strategies.

Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA, Deming DA.

Ther Adv Med Oncol. 2015 Sep;7(5):252-62. doi: 10.1177/1758834015591952. Review.

17.

Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.

Peeters M, Karthaus M, Rivera F, Terwey JH, Douillard JY.

Drugs. 2015 May;75(7):731-48. doi: 10.1007/s40265-015-0386-x. Review.

18.

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer.

Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S.

Br J Cancer. 2015 Jan 20;112(2):313-8. doi: 10.1038/bjc.2014.561. Epub 2014 Nov 20.

19.
20.

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.

Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero J.

Clin Cancer Res. 2014 Aug 15;20(16):4240-50. doi: 10.1158/1078-0432.CCR-13-2752. Epub 2014 Jun 11.

Supplemental Content

Support Center